See more : Electricité de France S.A. (EDF.VI) Income Statement Analysis – Financial Results
Complete financial analysis of RespireRx Pharmaceuticals Inc. (RSPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RespireRx Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rajkamal Synthetics Limited (RAJKSYN.BO) Income Statement Analysis – Financial Results
- Allied Security Innovations, Inc. (ADSV) Income Statement Analysis – Financial Results
- Diamcor Mining Inc. (DMIFF) Income Statement Analysis – Financial Results
- Landstar System, Inc. (LSTR) Income Statement Analysis – Financial Results
- Fujian Acetron New Materials Co., Ltd. (300706.SZ) Income Statement Analysis – Financial Results
RespireRx Pharmaceuticals Inc. (RSPI)
About RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.92K | 61.67K | 0.00 | 48.31K | 3.11M | 10.47M | 11.00K | 0.00 | 25.00K | 1.18M | 2.58M | 6.97B | 5.23M | 6.43M | 4.44M | 5.51M | 3.15M | 130.00K | 0.00 | 0.00 | 100.00K | 100.00K | 2.60M | 1.00M | 100.00K | 100.00K | 100.00K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.17K | 6.95K | 1.71K | 591.77 | 206.91 | 826.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -172.76K | 0.00 | 0.00 | 0.00 | 0.00 | 4.10M | 2.80M | 1.80M | 2.10M | 1.80M | 2.40M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.17K | -6.95K | 85.21K | 61.08K | -206.91 | 47.48K | 3.11M | 10.47M | 11.00K | 0.00 | 25.00K | 1.18M | 2.58M | 6.97B | 5.23M | 6.43M | 4.44M | 5.68M | 3.15M | 130.00K | 0.00 | 0.00 | -4.00M | -2.70M | 800.00K | -1.10M | -1.70M | -2.30M | 100.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 98.04% | 99.04% | 0.00% | 98.29% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 103.14% | 100.00% | 100.00% | 0.00% | 0.00% | -4,000.00% | -2,700.00% | 30.77% | -110.00% | -1,700.00% | -2,300.00% | 100.00% | 0.00% |
| Research & Development | 429.53K | 702.04K | 638.28K | 599.33K | 688.29K | 1.73M | 3.18M | 1.71M | 591.77K | 206.91K | 826.70K | 2.19M | 3.74M | 4.60M | 10.78M | 9.33M | 13.26M | 11.18M | 6.12B | 3.80M | 5.04M | 4.41M | 3.90M | 3.38M | 4.01M | 3.38M | 2.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 110.00K |
| General & Administrative | 1.15M | 1.86M | 2.68M | 1.14M | 1.49M | 2.52M | 5.30M | 3.62M | 3.82M | 932.97K | 1.95M | 3.19M | 4.55M | 3.74M | 4.26M | 4.32M | 3.38B | 3.39B | 2.29B | 2.62B | 2.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 220.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -397.00 | -82.00 | -3.37B | -3.39B | 0.00 | -2.62B | -2.44B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.15M | 1.86M | 2.68M | 1.14M | 1.49M | 2.52M | 5.30M | 3.62M | 3.82M | 932.97K | 1.95M | 3.19M | 4.55M | 3.74M | 4.26M | 4.32M | 4.62M | 3.56M | 2.29B | 2.62M | 2.44M | 2.43M | 1.81M | 1.40M | 1.58M | 1.71M | 1.64M | 2.90M | 2.00M | 1.40M | 1.30M | 900.00K | 0.00 | 1.30M | 220.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 167.62M | 1.11B | 0.00 | 0.00 | 0.00 | 172.76K | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 0.00 | 10.00K |
| Operating Expenses | 1.58M | 2.56M | 3.32M | 1.74M | 2.18M | 4.25M | 8.47M | 5.33M | 4.42M | 1.14M | 2.77M | 5.38M | 8.29M | 8.33M | 15.04M | 13.65M | 17.88M | 14.74M | 9.51B | 6.42M | 7.49M | 6.84M | 5.88M | 4.78M | 5.59M | 5.09M | 4.32M | 3.10M | 2.20M | 1.60M | 1.40M | 1.00M | 100.00K | 1.30M | 340.00K |
| Cost & Expenses | 1.58M | 2.56M | 3.32M | 1.74M | 2.18M | 4.25M | 8.47M | 5.33M | 4.42M | 1.14M | 2.77M | 5.38M | 8.29M | 8.33M | 15.04M | 13.65M | 17.88M | 14.74M | 9.51B | 6.42M | 7.49M | 6.84M | 5.71M | 4.78M | 5.59M | 5.09M | 4.32M | 7.20M | 5.00M | 3.40M | 3.50M | 2.80M | 2.50M | 1.30M | 340.00K |
| Interest Income | 603.82 | 724.77 | 545.68 | 404.66 | 0.00 | 0.00 | 8.00 | 9.00 | 0.00 | 0.00 | 92.00 | 1.86K | -8.50K | 16.58K | 443.06K | 678.05K | 645.82K | 637.37K | 0.00 | 0.00 | 72.14K | 254.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 603.82K | 724.77K | 545.68K | 404.66K | 136.24K | 102.23K | 586.35K | 902.70K | 117.31K | 56.34K | 196.98K | 4.02K | 1.63M | -8.44M | -14.60M | -12.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.93M | -4.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.00K |
| Depreciation & Amortization | 80.45K | 2.56M | 3.32M | 1.74M | 5.17K | 5.17K | 6.95K | 7.12K | 1.66K | -7.22K | 115.86K | 106.97K | 112.48K | 186.94K | 164.89K | 126.85K | 110.79K | 125.98K | 0.00 | 155.85K | 153.18K | 149.48K | 172.76K | 197.66K | 201.66K | 198.06K | 230.22K | -200.00K | -200.00K | -200.00K | -100.00K | 100.00K | 100.00K | 20.00K | 50.00K |
| EBITDA | -1.50M | -963.75K | -2.43M | -378.53K | -2.46M | -4.24M | -8.46M | -5.05M | -2.59M | -1.14M | -7.26M | -2.15M | 2.29M | -8.25M | -14.43M | -12.84M | -15.94M | -11.50M | -2.54B | -1.03M | -901.60K | -2.25M | -30.01K | -1.43M | -5.26M | -4.89M | -4.09M | -7.10M | -5.00M | -600.00K | -2.50M | -2.60M | -2.30M | -1.20M | -290.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,020.17% | -7,057.06% | 0.00% | -5,400.72% | -69.18% | 21.99% | -72,951.27% | 0.00% | -54,081.46% | -1,408.95% | -463.68% | -36.43% | -19.75% | -14.02% | -50.61% | -0.54% | -45.45% | -4,046.29% | 0.00% | 0.00% | -7,100.00% | -5,000.00% | -23.08% | -250.00% | -2,800.00% | -2,500.00% | -1,300.00% | 0.00% |
| Operating Income | -1.58M | -2.56M | -3.32M | -1.74M | -2.18M | -4.25M | -8.47M | -5.24M | -4.35M | -1.14M | -7.33M | -2.26M | 2.18M | -8.33M | -15.04M | -13.65M | -16.70M | -12.16M | -2.54B | -1.19M | -1.05M | -2.40M | -202.77K | -1.63M | -5.46M | -5.09M | -4.32M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.22M | -340.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,028.37% | -7,059.75% | 0.00% | -15,177.09% | -72.62% | 20.83% | -75,770.52% | 0.00% | -54,588.86% | -1,418.36% | -471.78% | -36.43% | -22.73% | -16.40% | -53.98% | -3.68% | -51.72% | -4,201.41% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,220.00% | 0.00% |
| Total Other Income/Expenses | -523.37K | -585.71K | -986.08K | -378.53K | -415.27K | -44.07K | -757.87K | -722.28K | 1.65M | -63.56K | -240.34K | 6.95K | -553.30K | -106.60K | 443.06K | 678.05K | 645.82K | 554.38K | 0.00 | 14.51K | 72.14K | 2.40M | 5.37K | 8.48K | 203.88K | 155.62K | 163.06K | 200.00K | 300.00K | 0.00 | 100.00K | 200.00K | 200.00K | 100.00K | 20.00K |
| Income Before Tax | -2.10M | -3.14M | -4.30M | -2.12M | -2.59M | -4.29M | -9.23M | -5.96M | -2.71M | -1.20M | -7.57M | -2.25M | 1.63M | -8.44M | -14.60M | -12.97M | -16.05M | -11.61M | 0.00 | -1.17M | -982.64K | -2.67M | -197.40K | -1.62M | -5.26M | -4.93M | -4.16M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.20M | -320.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,859.37% | -4,390.57% | 0.00% | -15,674.60% | -72.40% | 15.55% | -76,739.58% | 0.00% | -51,876.65% | -1,363.51% | -450.28% | 0.00% | -22.46% | -15.28% | -60.17% | -3.58% | -51.45% | -4,044.58% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,200.00% | 0.00% |
| Income Tax Expense | -80.45K | 724.77K | 545.68K | 404.66K | 279.02K | 44.07K | 757.87K | 722.28K | -1.65M | 7.22K | 4.85M | 2.25M | -1.63M | 8.44M | 14.60M | 12.97M | 16.05M | 11.61M | 0.00 | 1.17M | 982.64K | 2.67M | 197.40K | 1.62M | 5.26M | 4.93M | 4.16M | 6.80M | 4.70M | 800.00K | 2.40M | 2.60M | 2.20M | 1.20M | -50.00K |
| Net Income | -3.97M | -3.87M | -4.85M | -2.52M | -2.59M | -4.29M | -9.23M | -5.96M | -2.71M | -1.20M | -7.57M | -2.25M | 1.63M | -8.44M | -14.60M | -12.97M | -16.05M | -11.61M | 0.00 | -1.17M | -982.64K | -2.67M | -197.40K | -1.62M | -5.26M | -4.93M | -4.16M | -6.80M | -4.70M | -800.00K | -2.40M | -2.60M | -2.20M | -1.20M | -270.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,859.37% | -4,390.57% | 0.00% | -15,674.60% | -72.40% | 15.55% | -76,739.58% | 0.00% | -51,876.65% | -1,363.51% | -450.28% | 0.00% | -22.46% | -15.28% | -60.17% | -3.58% | -51.45% | -4,044.58% | 0.00% | 0.00% | -6,800.00% | -4,700.00% | -30.77% | -240.00% | -2,600.00% | -2,200.00% | -1,200.00% | 0.00% |
| EPS | -0.04 | -0.04 | -0.19 | -6.45 | -7.73 | -17.75 | -49.51 | -50.40 | -45.65 | -27.11 | -226.92 | -91.62 | 65.00 | -491.81 | -997.19 | -1.00K | -1.52K | -1.15K | 0.00 | -226.37 | -191.10 | -523.36 | -40.62 | -393.08 | -1.78K | -1.94K | -2.07K | -3.67K | -3.09K | -779.73 | -2.56K | -3.21K | -2.74K | -1.93K | -27.00 |
| EPS Diluted | -0.04 | -0.04 | -0.19 | -6.45 | -7.73 | -17.75 | -49.51 | -50.40 | -45.65 | -27.11 | -226.92 | -91.62 | 65.00 | -491.81 | -997.19 | -1.00K | -1.52K | -1.15K | 0.00 | -226.37 | -177.31 | -523.36 | -40.62 | -393.08 | -1.78K | -1.94K | -2.07K | -3.67K | -3.09K | -779.73 | -2.56K | -3.21K | -2.74K | -1.93K | -27.00 |
| Weighted Avg Shares Out | 111.32M | 88.35M | 25.86M | 390.85K | 335.11K | 241.83K | 186.40K | 118.29K | 59.31K | 44.32K | 33.37K | 24.61K | 22.67K | 17.16K | 14.64K | 12.96K | 10.57K | 10.05K | 7.13K | 5.19K | 5.14K | 5.11K | 4.86K | 4.13K | 2.95K | 2.54K | 2.01K | 1.85K | 1.52K | 1.03K | 937.00 | 810.00 | 802.00 | 621.00 | 10.00K |
| Weighted Avg Shares Out (Dil) | 111.32M | 88.35M | 25.86M | 390.85K | 335.11K | 241.83K | 186.40K | 118.29K | 59.31K | 44.32K | 33.37K | 24.61K | 22.67K | 17.16K | 14.64K | 12.96K | 10.57K | 10.05K | 7.13K | 5.19K | 5.54K | 5.11K | 4.86K | 4.13K | 2.95K | 2.54K | 2.01K | 1.85K | 1.52K | 1.03K | 937.00 | 810.00 | 802.00 | 621.00 | 10.00K |
RespireRX Pharmaceuticals establishes ResolutionRX in Australia to advance its cannabinoid program
RespireRx Pharmaceuticals (OTC:RSPI) Inc said that as of January 11, 2023, it has established a new, currently wholly-owned, unlisted public company in Australia called ResolutionRX. The company said that this is the first in a series of steps all for...
RespireRx Pharmaceuticals joins NIH program to find non-opioid pain-relief mechanisms to combat addiction
RespireRx Pharmaceuticals (OTC:RSPI) Inc announced that it has been accepted into the National Institute of Health's (NIH) Helping to End Addiction Long-term (HEAL) Initiative. The HEAL initiative is operated by the National Institute of Neurological Disorders and Stroke (NINDS), part...
RespireRx Pharmaceuticals signs letter of intent with Australian CRO to study drug for treating obstructive sleep apnea
RespireRx Pharmaceuticals (OTCQB:RSPI) said it has signed a letter of intent with a bespoke clinical research organization in Australia that focuses on cannabinoid and psychedelic clinical research. Upon reaching a definitive contract, RespireRx said it will make a US$50,000 deposit...
RespireRx Pharmaceuticals says its obstructive sleep apnea drug dronabinol featured in Sleep Review magazine free e-book
RespireRx Pharmaceuticals (OTCQB:RSPI) Inc announced that its dronabinol obstructive sleep apnea (OSA) program has been featured in a free e-book published in the June 13, 2022, edition of Sleep Review magazine. The e-book, entitled 'How Close Are We to Drug Therapy for Obstructive...
RespireRx Pharmaceuticals Interim CEO talks AMPAkines in treating GRI disorders at virtual conference
RespireRx Pharmaceuticals (OTCQB:RSPI) Inc said Chief Scientific Officer and Interim CEO Arnold Lippa was an invited speaker at the 2022 GRI Virtual Conference last month, where he discussed the potential use of AMPAkines for the treatment of certain disorders. Lippa described...
RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics.
Glen Rock, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased...
RespireRx Pharmaceuticals highlights experimental data suggesting its GABAkine KRM-II-81 could be game-changing for tinnitus patients
RespireRx Pharmaceuticals (OTCQB:RSPI) Inc has announced that members of the company's scientific team have published a new article highlighting the potential of novel treatments, including the company's own GABAkine KRM-II-81 for tinnitus, the perception of sound in the absence of...
RespireRx Pharmaceuticals files provisional patent application for lipid-based formulation technology to develop cannabinoids
RespireRx Pharmaceuticals (OTCQB:RSPI) Inc announced that it has filed a provisional patent application for a novel lipid-based formulation technology (LFT) that may be used to improve the solubility and bioavailability of poorly soluble drugs, particularly cannabinoids. Low aqueous solubility is...
RespireRx Pharmaceuticals notes publication of paper on newest GABAkine analog which protects against seizures and lethality
RespireRx Pharmaceuticals (OTCQB:RSPI) Inc has noted the publication of a paper detailing the company's newest candidate D5-KRM-II-81, which is a so-called GABAkine - a type of medicine which enhances the inhibitory neurotransmitter in the brain. This latest asset is a...
RespireRx Pharmaceuticals notes publication of paper on GABAkine KRM-II-81, which it is advancing for epilepsy and pain
RespireRx Pharmaceuticals (OTCQB:RSPI) Inc revealed that scientists associated with the company have published a paper about its candidate KRM-II-81, which is a so-called GABAkine - a type of medicine which enhances the inhibitory neurotransmitter in the brain. RespireRx is advancing a...
Source: https://incomestatements.info
Category: Stock Reports